ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
02 mars 2021 16h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
25 févr. 2021 07h00 HE
|
ProQR Therapeutics N.V.
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from...
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference
18 déc. 2020 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Third Quarter 2020 Operating and Financial Results
16 nov. 2020 07h00 HE
|
ProQR Therapeutics N.V.
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021Enrollment completed for QR-421a...
ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)
02 nov. 2020 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer
05 oct. 2020 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Virtual Presentations at Scientific Conferences
24 sept. 2020 16h10 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Announces Second Quarter 2020 Operating and Financial Results
06 août 2020 16h30 HE
|
ProQR Therapeutics N.V.
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;Strategic...
ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy
21 juil. 2020 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
14 juil. 2020 16h30 HE
|
ProQR Therapeutics N.V.
Extends ProQR’s cash runway into 2023ProQR can trigger conversion of the debt to equity at $7.88 per share, under certain conditions LEIDEN, Netherlands & CAMBRIDGE, Mass. , July 14, 2020 ...